Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Agomelatine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A known ✓ | P48039 | 18/20 | 0.95 |
| ▸ | MTNR1B known ✓ | P49286 | 9/20 | 0.95 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.95 |
| ▸ | HTR2B | P41595 | 1/20 | 0.95 |
| ▸ | NQO2 | P16083 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Agomelatine SCHEMBL1289524 | 0.99 | MTNR1A (0.97) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| Agomelatine SCHEMBL28116100 | 0.99 | MTNR1A (0.97) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| Agomelatine SCHEMBL2454293 | 0.97 | MTNR1A (0.95) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| Agomelatine SCHEMBL27215745 | 0.97 | MTNR1A (0.95) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| Agomelatine SCHEMBL1158495 | 0.97 | MTNR1A (1.00) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| Agomelatine SCHEMBL27844916 | 0.97 | MTNR1A (1.00) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| Agomelatine SCHEMBL29930659 | 0.97 | MTNR1A (1.00) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| Agomelatine SCHEMBL114476 | 0.97 | MTNR1A (1.00) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| Agomelatine SCHEMBL28522576 | 0.96 | MTNR1A (0.97) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| Agomelatine SCHEMBL27855409 | 0.96 | MTNR1A (0.97) | MTNR1AMTNR1BHTR2CHTR2BNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102958911-B | Agomelatine hydrogen chloride hydrate and preparation method thereof | LES LABORATOIRES SERVIER (FR) | 2015-11-25 | — | — | CN | claimed |
| EP-2547649-B1 | AGOMELATINE HYDROCHLORIDE HYDRATE AND PREPARATION THEREOF | SERVIER LAB (FR) | 2014-11-19 | — | — | EP | claimed |
| US-8729131-B2 | Agomelatine hydrochloride hydrate and preparation thereof | LES LABORATOIRES SERVIER (FR) | 2014-05-20 | — | — | US | claimed |
| CN-102958911-A | Agomelatine hydrochloride hydrate and preparation thereof | SERVIER LAB | 2013-03-06 | — | — | CN | claimed |
| EP-2547649-A1 | AGOMELATINE HYDROCHLORIDE HYDRATE AND PREPARATION THEREOF | Les Laboratoires Servier (FR) | 2013-01-23 | — | — | EP | claimed |
| US-20130005820-A1 | AGOMELATINE HYDROCHLORIDE HYDRATE AND PREPARATION THEREOF | LES LABORATOIRES SERVIER (FR) | 2013-01-03 | — | — | US | claimed |
| WO-2011113362-A1 | AGOMELATINE HYDROCHLORIDE HYDRATE AND PREPARATION THEREOF | LES LABORATOIRES SERVIER (FR) | 2011-09-22 | — | — | WO | claimed |
| CN-106692039-B | Agomelatine oral liquid preparation and preparation method and application thereof | 恩瑞生物医药科技（上海）有限公司 | 2021-04-02 | — | — | CN | disclosed |
| CN-106420597-A | Aqueous agomelatine solution, and preparation method and application thereof | 恩瑞生物医药科技（上海）有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-102958911-B | Agomelatine hydrogen chloride hydrate and preparation method thereof | LES LABORATOIRES SERVIER (FR) | 2015-11-25 | — | — | CN | disclosed |
| CN-102958911-B | Agomelatine hydrogen chloride hydrate and preparation method thereof | LES LABORATOIRES SERVIER (FR) | 2015-11-25 | — | — | CN | disclosed |
| CN-102958911-B | Agomelatine hydrogen chloride hydrate and preparation method thereof | LES LABORATOIRES SERVIER (FR) | 2015-11-25 | — | — | CN | disclosed |
| EP-2934502-A1 | PROCESS FOR PREPARARING N-(2-(7-METHOXY-1-NAPHTHALENYL)ETHYL) ACETAMIDE AND SOLID FORMS THEREOF | Laboratorios Lesvi S.L. (ES) | 2015-10-28 | — | — | EP | disclosed |
| EP-2547649-A1 | AGOMELATINE HYDROCHLORIDE HYDRATE AND PREPARATION THEREOF | Les Laboratoires Servier (FR) | 2013-01-23 | — | — | EP | disclosed |
| US-20130005820-A1 | AGOMELATINE HYDROCHLORIDE HYDRATE AND PREPARATION THEREOF | LES LABORATOIRES SERVIER (FR) | 2013-01-03 | — | — | US | disclosed |
| US-20130005820-A1 | AGOMELATINE HYDROCHLORIDE HYDRATE AND PREPARATION THEREOF | LES LABORATOIRES SERVIER (FR) | 2013-01-03 | — | — | US | disclosed |
| WO-2011113362-A1 | AGOMELATINE HYDROCHLORIDE HYDRATE AND PREPARATION THEREOF | LES LABORATOIRES SERVIER (FR) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011113362-A1 | AGOMELATINE HYDROCHLORIDE HYDRATE AND PREPARATION THEREOF | LES LABORATOIRES SERVIER (FR) | 2011-09-22 | — | — | WO | disclosed |
| CN-102190594-A | Agomelatine hydrogen chloride hydrate and preparation method thereof | SHANGHAI INST PHARM INDUSTRY | 2011-09-21 | — | — | CN | disclosed |
| CN-102190594-A | Agomelatine hydrogen chloride hydrate and preparation method thereof | SHANGHAI INST PHARM INDUSTRY | 2011-09-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005820-A1 | AGOMELATINE HYDROCHLORIDE HYDRATE AND PREPARATION THEREOF | ADCYAP1R1, MC2R, MC4R | MTNR1A 23/4885MTNR1B 27/4885HTR2C 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.